INOGEN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Inogen, Inc. – iCrowdNewswire
Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

Mar 16, 2019 9:00 AM ET

INOGEN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Inogen, Inc.


INOGEN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Inogen, Inc.

Legal Newswire

iCrowd Newswire - Mar 16, 2019

NEW YORK,  — Wolf Haldenstein Adler Freeman & Herz LLP announces that a  class action  lawsuit has been filed against Inogen, Inc. (“Inogen” or the “Company”) (Nasdaq: INGN) in the United States District Court for the Central  District of California  on behalf of  those who purchased  or acquired  Inogen between November 8,  2017 and February  26, 2019, inclusive (the “Class Period”).

Investors   who purchased shares of Inogen, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website www.whafh.com.

If you have incurred losses in the shares of Inogen, Inc., you may, no later than May 6, 2019, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Inogen, Inc.

The filed Complaint alleges that Defendants failed to disclose that:

As a result of this information being withheld from the market, the price of Inogen common stock was artificially inflated to more than $282 per share during the Class Period.

On November 6, 2018, Inogen announced its third quarter 2018 financial results and, while the  quarterly financial  results were in  line with  expectations, Defendants revealed that the growth in domestic business-to-business sales  to HME providers  had  slowed  and  reduced Inogen’s  guidance  for  fiscal  2018 adjusted EBITDA.

As a result of this news, the price of Inogen common stock fell over 19%, or $37.44 per share, to close at $155.86 per share. 

Then, following the publication of detailed investigative reports by stock  analysts on February  8, 2019  and February  12, 2019,  which challenged,  among  other things, the size of Inogen’s actual TAM,  the basis for its prior TAM  claims, and the source of its  Class Period sales growth,  the price of Inogen  common stock declined further to close at $138.05 per share on February 12, 2019.

On  February 26,  2019, after  the close  of trading,  Inogen  announced disappointing fourth  quarter  and  fiscal year  2018  financial  results  and significantly reduced its previously provided fiscal 2019 net income guidance. Inogen’s CEO also backtracked on the Company’s prior TAM estimate of 2.5 to 3 million patients, and blamed Inogen’s poor domestic business-to-business sales on order activity that slowed from one national homecare provider.

On  this news, the price of Inogen common stock fell an additional $33.77 per share, to close of $106.28 per share on February 27, 2019.

Follow the firm and learn about newly filed cases on Twitter and Facebook.

Wolf Haldenstein Adler Freeman & Herz LLP  has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

Contact Information:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774








Tags:    Wire, Legal Newswire, United States, English